$338 Million is the total value of Endurant Capital Management LP's 60 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IART | New | INTEGRA LIFESCIENCES HLDGS C | $13,298,000 | – | 281,608 | +100.0% | 3.93% | – |
| IWM | New | ISHARES TRput | $12,058,000 | – | 80,500 | +100.0% | 3.57% | – |
| CNMD | New | CONMED CORP | $6,388,000 | – | 81,205 | +100.0% | 1.89% | – |
| KIDS | New | ORTHOPEDIATRICS CORP | $5,821,000 | – | 126,764 | +100.0% | 1.72% | – |
| XBI | New | SPDR SER TRput | $5,794,000 | – | 52,000 | +100.0% | 1.71% | – |
| PDCO | New | PATTERSON COS INC | $3,939,000 | – | 163,415 | +100.0% | 1.16% | – |
| VAPO | New | VAPOTHERM INC | $3,645,000 | – | 125,675 | +100.0% | 1.08% | – |
| PETS | New | PETMED EXPRESS INC | $3,348,000 | – | 105,895 | +100.0% | 0.99% | – |
| DGX | New | QUEST DIAGNOSTICS INC | $3,325,000 | – | 29,041 | +100.0% | 0.98% | – |
| MGNX | New | MACROGENICS INC | $2,453,000 | – | 97,374 | +100.0% | 0.72% | – |
| TBIO | New | TRANSLATE BIO INC | $2,405,000 | – | 176,710 | +100.0% | 0.71% | – |
| ALC | New | ALCON AG | $2,185,000 | – | 38,373 | +100.0% | 0.65% | – |
| New | APTOSE BIOSCIENCES INC | $2,071,000 | – | 345,172 | +100.0% | 0.61% | – | |
| IMUX | New | IMMUNIC INC | $2,060,000 | – | 110,911 | +100.0% | 0.61% | – |
| KNSA | New | KINIKSA PHARMACEUTICALS LTD | $1,800,000 | – | 117,480 | +100.0% | 0.53% | – |
| DVA | New | DAVITA INC | $1,799,000 | – | 21,002 | +100.0% | 0.53% | – |
| LMNX | New | LUMINEX CORP DEL | $1,788,000 | – | 68,131 | +100.0% | 0.53% | – |
| ALBO | New | ALBIREO PHARMA INC | $1,740,000 | – | 52,131 | +100.0% | 0.52% | – |
| ARCT | New | ARCTURUS THERAPEUTICS HLDGS | $1,479,000 | – | 34,485 | +100.0% | 0.44% | – |
| SAGE | New | SAGE THERAPEUTICS INC | $1,442,000 | – | 23,588 | +100.0% | 0.43% | – |
| CRTX | New | CORTEXYME INC | $1,091,000 | – | 21,827 | +100.0% | 0.32% | – |
| AXGN | New | AXOGEN INC | $817,000 | – | 70,209 | +100.0% | 0.24% | – |
| INBX | New | INHIBRX INC | $647,000 | – | 35,935 | +100.0% | 0.19% | – |
| PNTG | New | PENNANT GROUP INC | $528,000 | – | 13,699 | +100.0% | 0.16% | – |
| ALRN | New | AILERON THERAPEUTICS INC | $340,000 | – | 263,439 | +100.0% | 0.10% | – |
| CRBP | New | CORBUS PHARMACEUTICALS HLDGS | $162,000 | – | 89,886 | +100.0% | 0.05% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| LABORATORY CORP AMER HLDGS | 31 | Q2 2023 | 8.7% |
| ELEVANCE HEALTH INC | 29 | Q3 2023 | 8.8% |
| BECTON DICKINSON & CO | 28 | Q2 2023 | 9.8% |
| MCKESSON CORP | 27 | Q1 2023 | 4.4% |
| CENCORA INC | 26 | Q3 2023 | 5.9% |
| HOLOGIC INC | 24 | Q3 2023 | 7.5% |
| JOHNSON & JOHNSON | 24 | Q4 2021 | 5.5% |
| ZIMMER HLDGS INC | 23 | Q3 2023 | 7.5% |
| BOSTON SCIENTIFIC CORP | 22 | Q3 2023 | 5.5% |
| DAVITA INC | 22 | Q1 2021 | 4.9% |
View Endurant Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| AZIYO BIOLOGICS, INC. | March 21, 2023 | 576,253 | 4.9% |
| Oxford Immunotec Global PLCSold out | February 17, 2021 | 0 | 0.0% |
View Endurant Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-07 |
| SC 13D/A | 2024-04-10 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13D/A | 2023-09-08 |
| 13F-HR | 2023-08-14 |
| 3/A | 2023-05-24 |
| 13F-HR | 2023-05-15 |
| 3 | 2023-05-15 |
| SC 13D | 2023-05-15 |
View Endurant Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.